icddr,b’s research leads to approval of fourth single dose HPV Vaccine for public use
The vaccine, produced by Innovax in China, has now been recommended by the WHO as a single-dose vaccine, offering a new option for countries facing vaccine supply shortages, according to a press release.
Breakthrough research conducted by icddr,b has played a key role in the World Health Organization's (WHO) approval of Cecolin®, the fourth HPV vaccine, for single-dose public use.
The approval marks a significant advancement in the fight against cervical cancer, which claims the life of a woman every two minutes, with 90% of these deaths occurring in low- and middle-income countries.
The CVIA 087 (CHOISES) trial, led by icddr,b in collaboration with PATH and partners in Ghana from 2021 to 2023, provided the critical data needed for the approval of Cecolin®. The vaccine, produced by Innovax in China, has now been recommended by the WHO as a single-dose vaccine, offering a new option for countries facing vaccine supply shortages, according to a press release.
"Our research has proven the safety and efficacy of Cecolin® as a single-dose vaccine, providing a viable option for countries struggling with vaccine supply shortages," said Dr K Zaman, senior scientist at icddr,b and lead investigator of the trial.
"Bangladesh's involvement in this global breakthrough is a proud moment, and we hope it inspires confidence in the HPV vaccination programme."
The approval of Cecolin® is expected to have a profound impact on global immunisation policy, especially in countries where access to vaccines is limited. WHO Director-General Dr Tedros Adhanom Ghebreyesus highlighted the importance of the approval, stating, "Unlike most other cancers, we have the ability to eliminate cervical cancer, along with its painful inequities. By adding another option for a one-dose HPV vaccination schedule, we have taken another step closer to consigning cervical cancer to history."
Dr Tahmeed Ahmed, executive director of icddr,b, stressed the importance of the HPV vaccination programme in Bangladesh, where the government is offering free vaccines to girls aged 10-14 or those studying in grades 5-9.
"This is a critical opportunity to protect our daughters from cervical cancer. Vaccination is our strongest defence, and I encourage all parents and guardians to ensure their girls receive this life-saving vaccine. It's a priority not only for those eligible for the free programme but for all who are at risk."
With over 660,000 cases of cervical cancer reported globally each year, and 95% of these cases caused by HPV, the need for accessible vaccines has never been more urgent. The majority of deaths occur in low- and middle-income countries, further underscoring the importance of Cecolin®'s approval as a cost-effective solution.
The WHO's announcement marks a major milestone in global health, allowing more countries to access affordable and effective HPV vaccines. icddr,b's research continues to contribute to this mission, shaping public health policies and saving lives.